Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) as a single agent
b. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
c. Abemaciclib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Carboplatin or Cisplatin as a single agent
h. Eribulin as a single agent or in combination
i. Everolimus + Exemestane
j. Fulvestrant as a single agent
k. Lapatinib
l. Neratinib
m. Parp Inhibitors (Olaparib/Talazoparib)
n. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
o. Palbociclib + Fulvestrant
p. Pembrolizumab
q. Pertuzumab + Trastuzumab + Docetaxel
r. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
s. Ribociclib + Fulvestrant
t. Sacituzumab Govitecan
u. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Vinorelbine as a single agent
z. Any other active systemic anti-cancer therapy
Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrazole, exemestane, letrozole) as a single agent?
